AstaZeneca Fasenra Approval

AstraZeneca (AZN) product Fasenra (bevacizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) - a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal.

The approval in the United States FDA was based on positive results from the MANDARA Phase III trial published in . . .